(NASDAQ: AVIR) Atea Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 87.28%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.65%.
Atea Pharmaceuticals's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast AVIR's revenue for 2025 to be $1,793,910,910, with the lowest AVIR revenue forecast at $1,793,910,910, and the highest AVIR revenue forecast at $1,793,910,910.
In 2026, AVIR is forecast to generate $2,706,111,947 in revenue, with the lowest revenue forecast at $1,454,453,876 and the highest revenue forecast at $3,957,854,482.